Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kolodziej Maciej, Opalinska Marta, Mikolajczak Renata, Hubalewska-Dydejczyk Alicja, Dedecjus Marek, Kowalska Aldona, Saracyn Marek, Garnuszek Piotr, Cieszykowska Izabela, Januszkiewicz-Caulier Joanna, Dlugosinska Joanna, Durma Adam Daniel, Jozwik-Plebanek Katarzyna, Mroz Adrianna, Janiak Katarzyna, Gasior-Perczak Danuta, Trofimiuk-Muldner Malgorzata, Sowa-Staszczak Anna, Braziewicz Janusz, Lenda-Tracz Wioletta, Kacperski Krzysztof, Budzynska Anna, Kubik Agata, Pastusiak Patrycja, Chalewska Wioletta, Borkowska Anna, Cegla Paulina, Walecka-Mazur Agata, Szczodry Artur, Kaminski Grzegorz
Аннотация
METHODS: DUONEN is an ongoing multicenter, randomized phase 3 trial (N = 92 planned; 56 analyzed) comparing standard fixed-activity [177Lu]Lu-DOTA-TATE (arm A) with three dosimetry-guided regimens: arm B (177Lu+90Y, variable 90Y); arm C (177Lu+90Y, variable 177Lu); arm D (variable 177Lu). Organ dosimetry was performed after each cycle, with per-cycle activity modifications to respect kidney (23 Gy) and marrow (2 Gy) thresholds. Safety was assessed by laboratory, renal, and hepatic parameters.
RESULTS: Activity reductions predominated in arms B and C, while increases were common in arm D. Median cumulative kidney and marrow doses were highest in arm C (29.1 Gy and 0.79 Gy, respectively), driven by 90Y contribution. Hematologic declines were observed across all arms, most prominently in lymphocytes and platelets, and correlated with marrow dose but not with categorical dose modifications. Renal function remained stable, and no clinically relevant hepatotoxicity occurred.
CONCLUSIONS: This interim analysis demonstrates the feasibility and safety of dosimetry-guided PRRT strategies, including individualized 177Lu escalation and tandem 90Y/177Lu. DUONEN provides the first randomized prospective evidence for isotope- and patient-tailored PRRT dosing. Long-term follow-up will clarify their impact on efficacy.
CLINICAL TRIAL REGISTRATION: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-006068-99, identifier 2020-006068-99.